Advanced Search
Contact | Corporate | Help

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

Sponsors:
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • Genentech
  • Biogen Idec
Phases:
  • Phase II
IndicationsAcronym:
  • Myositis
  • Dermatomyositis
  • Polymyositis
  • Juvenile Dermatomyositis
Age Groups:
  • Child
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Rituximab
  • Drug: Placebo
Enrollment:
202

Additional information about NCT00106184.


SourceSolution © 2008-2012